Eastern Canadian Colorectal Cancer Consensus Conference: Application of New Modalities of Staging and Treatment of Gastrointestinal Cancers
T. Di Valentin(Sunnybrook Health Science Centre), Tim Asmis(Queen's University), N. Finn, Carman A. Giacomantonio(Dalhousie University), David W. Hedley(Ontario Institute for Cancer Research), P. Champion(Royal Marsden Hospital), Rakesh Goel(Ottawa Hospital), Rachel Goodwin(University of Ottawa), Steven Gallinger(Ontario Institute for Cancer Research), James Biagi(Queen's University), Michael P. Thirlwell(McGill University Health Centre), Brian Colwell, Heather Ostic(Ottawa Hospital), Stephen Welch(Cancer Care Ontario), F. Aubin(Centre Hospitalier Universitaire de Besançon), Kartik Jhaveri, Ève St‐Hilaire(Dr. Georges-L.-Dumont University Hospital Centre), Axel Grothey(Campbell Clinic), Derek J. Jonker(University of Ottawa), Nazik Hammad(St. Michael's Hospital), M. Rother(Credit Valley Hospital), Sharlene Gill(Deventer Ziekenhuis), Mustapha Tehfé(Centre Hospitalier de l’Université de Montréal), C. Cripps(Canadian Partnership Against Cancer), Nirit Yarom(The King's College), L. Grimard(Ottawa Hospital), Mary Lesperance(University of Victoria), Ronald L. Burkes(Mount Sinai Hospital), Dominique Frechette, Nancy Perrin(Oregon Health & Science University), Abdullah A. Alsharm(Ottawa Hospital), Yasmin Alam(Ottawa Hospital), M. Dorreen(Saint John Regional Hospital), Y.J. Ko(Ottawa Hospital), Susan Bourque(BC Cancer Agency), Jean A. Maroun(American Society of Clinical Oncology), Chris Booth(Ottawa Hospital), S.A.M. Arif(Ottawa Hospital), M Dallaire(Cegep de Sept Iles), J. Gapski(Ottawa Hospital)
Cited by 4
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k